Abnormalities of coagulation and fibrinolysis in insulin resistance

Diabetes Care

Volumn 22, Issue SUPPL. 3, 1999, Pages

  Yudkin, John S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CYTOKINE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CONFERENCE PAPER; DYSLIPIDEMIA; ENDOTHELIUM CELL; FIBRINOLYSIS; HORMONE ACTION; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIVER CELL; METABOLIC DISORDER; PROTEIN EXPRESSION; PROTEIN SECRETION; VASODILATATION;

BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; FIBRINOGEN; FIBRINOLYSIS; HUMANS; INSULIN RESISTANCE; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 0032936725     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall Study Lancet i:1373-1376, 1980
2. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141, 1979
3. Ducimetière P, Eschwège E, Papoz L, Richard J-L, Claude CR, Rosselin G: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19:205-210, 1980
4. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154-160, 1979
5. Després J-P, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
6. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959-965, 1993
7. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
8. Hillson RM, Hockaday TDR, Mann JI, Newton DJ: Hyperinsulinaemia is associated with development of electrocardiographic abnormalities in diabetics. Diabetes Res 1:143-149, 1984
9. Stout RW: Insulin and atheroma: 20 year perspective. Diabetes Care 13:631-655, 1990
10. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii:3-9, 1987
11. Gray RP, Yudkin JS, Patterson DLH: Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic subjects. Br Heart J 69:228-232, 1993
12. Gray RP, Patterson DLH, Yudkin JS: Plasminogen activator inhibitor activity in diabetic and non-diabetic survivors of myocardial infarction. Arterioscler Thromb 13:415-420, 1993
13. Gray RP, Yudkin JS, Patterson DL: Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 70:530-536, 1993
14. Juhan Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic subjects: relationship with plasma insulin. Thromb Haemost 61:370-373, 1989
15. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945-949, 1993
16. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
17. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I: Stimulating effect of oxidised low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 11:1821-1829, 1991
18. Nordt T, Schneider D, Sobel E: Augmentation of synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation 89:321-330, 1994
19. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG: Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 62:723-728, 1989
20. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I: Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: mctformin inhibits the stimulating effect of insulin. J Clin Invest 91:2185-2193, 1993
21. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease Diabetes 46:860-867, 1997
22. Wagner DD: Cell biology of von Willebrand factor. Ann Rev Cell Biol 6:217-246, 1990
23. Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS: Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 46 (Suppl 2):S9-S13, 1997
24. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the ECAT Study Group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995
25. Vallance P, Collier J, Bhagat K: Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 349:1391-1392, 1997
26. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb 13:1865-1873, 1993
27. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Mareucci G, Wu KK: Associations of factor VIII and von Willebrand factor with age, race, sex. and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (AR1C) Study. Thromb Haemost 70:380-385, 1993
28. Yudkin JS: Lipids, thrombosis and cardiovascular disease in diabetes. Proc Nutr Soc 56:273-280, 1997
29. Nosadini R, Cipollina MR, Solini A, Sambataro M, Morocutti A, Doria A, Fioretto P, Brocco E, Muollo B, Frigato F: Close relationship between microalbummuria and insulin resistance in essential hypertension and non-insulin dependent diabetes. J Am Soc Nephrol 3:S56-S63, 1992
30. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti GC: Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883-887, 1993
31. Foyle W-J, Carstensen E, Fernández MC, Yudkin JS: Longitudinal study of associations of microalbuminuria with the insulin resistance syndrome and sodium-lithium countertranspon in nondiabetic subjects Arterioscler Thromb Vasc Biol 15:1330-1337, 1995
32. Stehouwer CDA, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.Lancet 340:319-323, 1992
33. Simon BC, Cunningham LD, Cohen RA: Oxidised low-density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 86:75-79, 1990
34. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatly acid levels impair endothelium-dependent vasodilatation J Clin Invest 100:1230-1239, 1997
35. Jansson PA, Fowelin JP, von Schenck HP, Smith UP, Lönnroth PN: Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Diabetes 42:1469-1473, 1993
36. Yang YJ, Hope ID, Ader M, Bergman RN: Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 84:1620-1628, 1989
37. Baron AD: Cardiovascular actions of insulin in humans: implications for insulin sensitivity and vascular tone. Ballière's Clin Endocrinol Metab 7:961-985, 1993
38. 18F]fluoro-2-deoxy-D-glucose and positron emission tomography. Diabetes 45:1471-1477, 1996
39. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41:1076-1083, 1992
40. Reymer PWA, Gagne E, Groenemayer BE, Zhang H, Forsyth I, Jansen H, Seidell JC, Kromhout D, Lie KE, Kastelein J, Hayden MR: A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL-cholesterol levels in premature atherosclerosis. Nat Genet 10:28-30, 1995
41. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N: Basal nitric oxide synthesis in essential hypertension. Lancet 349:837-842, 1997
42. Heinrich PC, Castell JY, Andus T: Interleukin-6 and the acute phase response. Biochem J 265:621-636, 1990
43. Thomas A, Kelleher C, Green F, Meade TW, Humphries SE: Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 70:915-920, 1993
44. Mohamed-Ali V, Gould MM, Gillies S, Goubet S, Yudkin JS, Haines AP: Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects: evidence against a modulating role for insulin. Diabetologia 38:1110-1116, 1995
45. Rillaerts E, Van Gaal L, Xiang DZ, Vansant G, De Leeuw I: Blood viscosity in human obesity: relation to glucose tolerance and insulin status. Int J Obes 13:739-745, 1989
46. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273-278, 1990
47. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW: Creative protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunctionArterioscler Thromb Vasc Biol. In press
48. van der Poll T, van Deventer SJH, Pasterkamp G, van Mourik JA, Büller HR, ten Cate JW: Tumour necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 67:623-626, 1992
49. Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, Stewart DJ: Lack of role for nitric oxide (NO) in the selective destabilisation of endothelial NO synthase mRNA by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 15:52-57, 1995
50. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscalla P. Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Cillberto G, Mantovani A: Role of 1L-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:1-20, 1997
51. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link? Lancet 350:430-436, 1997
52. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumour necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
53. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A. Walker MM, Reed MJ: Aromatase activity and interleukin-6 production by normal and malignant breast tissue. J Clin Endocrinol 9:61-72, 1995
54. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995
55. Mohamed-Ali V, Goodrick S, Rawesh A, Miles JM, Katz D, Yudkin JS, Coppack SW: Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-α in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997
56. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278, 1994
57. Hotamisligil GL, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271:665-668. 1996
58. Kawakami M, Pekala PH, Lane MD, Cerami A: Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A 82:912-916, 1982
59. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D: Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 52:4113-4116, 1992
60. Van Snick J: Interleukin-6: an overview. Ann Rev Immunol 8:253-278, 1990
61. Samad F, Yamamoto K, Loskutoff DJ: Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 97:37-46, 1996
62. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
63. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885, 1996
64. Groop LC, Saloranta C, Shank M, Bonadonna C, Ferrannini H, DeFronzo RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72:96-107, 1991
65. UK Prospective Diabetes Study (UKPDS) Group 33: Intensive blood-glucose control with sulphonylureas on insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998